GH Research PLC (NASDAQ:GHRS – Get Rating) – Research analysts at HC Wainwright boosted their FY2022 earnings per share estimates for shares of GH Research in a research note issued to investors on Tuesday, November 15th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.39) per share for the year, up from their previous estimate of ($0.52). HC Wainwright has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for GH Research’s Q1 2023 earnings at ($0.15) EPS, Q2 2023 earnings at ($0.15) EPS, Q3 2023 earnings at ($0.16) EPS, Q4 2023 earnings at ($0.11) EPS, FY2023 earnings at ($0.56) EPS, FY2024 earnings at ($0.86) EPS, FY2024 earnings at ($0.86) EPS, FY2025 earnings at ($1.32) EPS, FY2025 earnings at ($1.32) EPS and FY2026 earnings at ($1.24) EPS.
GH Research Trading Down 5.8 %
Shares of GH Research stock opened at $10.16 on Thursday. GH Research has a 1 year low of $8.72 and a 1 year high of $30.43. The stock has a 50-day moving average price of $11.48 and a 200 day moving average price of $11.62. The company has a market cap of $513.29 million, a P/E ratio of -50.80 and a beta of 0.88.
Institutional Investors Weigh In On GH Research
Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its stake in shares of GH Research by 277.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the company’s stock worth $39,000 after purchasing an additional 2,486 shares in the last quarter. Tortoise Investment Management LLC purchased a new stake in shares of GH Research during the 2nd quarter worth about $41,000. Exchange Traded Concepts LLC raised its stake in shares of GH Research by 373.4% during the 2nd quarter. Exchange Traded Concepts LLC now owns 4,885 shares of the company’s stock worth $49,000 after purchasing an additional 3,853 shares in the last quarter. Bank of America Corp DE raised its stake in shares of GH Research by 31,790.0% during the 1st quarter. Bank of America Corp DE now owns 6,378 shares of the company’s stock worth $116,000 after purchasing an additional 6,358 shares in the last quarter. Finally, Virtus ETF Advisers LLC raised its stake in shares of GH Research by 48.8% during the 2nd quarter. Virtus ETF Advisers LLC now owns 9,952 shares of the company’s stock worth $99,000 after purchasing an additional 3,265 shares in the last quarter. 70.08% of the stock is owned by hedge funds and other institutional investors.
GH Research Company Profile
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
- Get a free copy of the StockNews.com research report on GH Research (GHRS)
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.